TOMI Secures $750K Deal with Eye Health Firm, Eyes $1.7M Expansion
Event summary
- TOMI closed a $750K deal with an unnamed global eye health company for SteraMist systems across two U.S. facilities.
- The customer signed a recurring consumable agreement, establishing a contracted revenue stream.
- Additional orders could bring total revenue to $960K–$1.7M by year-end 2026.
- The progression follows a typical pattern: handheld units → facility expansion → integrated systems.
- TOMI’s BIT Solution platform was validated after initial success at the first facility.
The big picture
TOMI’s deal with a global eye health firm underscores the growing demand for automated disinfection in regulated manufacturing. The structured adoption—from handheld units to whole-room systems—mirrors trends in pharma and biotech, where performance validation drives facility-wide rollouts. The recurring consumable agreement also highlights a shift toward predictable revenue streams in the infection prevention market.
What we're watching
- Execution Risk
- Whether TOMI can convert prospective orders into actual revenue by year-end 2026.
- Market Validation
- How this deal’s progression model applies to other regulated manufacturing clients.
- Recurring Revenue
- The pace at which consumable agreements expand TOMI’s contracted revenue base.
